Recursion Pharmaceuticals Aktie News
4,71 $
4,27 %
vorgestern
Nasdaq,
5. Dezember, 22:18 Uhr
Was hinter der Kursbewegung steckt Beta
tracken
Recursion Pharmaceuticals Aktie News
Positiv
The Motley Fool
●
3 Tage alt
Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.
Neutral
GlobeNewsWire
●
6 Tage alt
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GM...
Positiv
The Motley Fool
●
13 Tage alt
Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers.
Neutral
Seeking Alpha
●
15 Tage alt
Recursion Pharmaceuticals, Inc. ( RXRX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:30 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good morn...
Neutral
The Motley Fool
●
18 Tage alt
Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though.
Positiv
Seeking Alpha
●
19 Tage alt
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating losses, and significant share dilution, with profitability likely several years away despite strong partnerships and a robust balance sheet. RXRX stock trades at a steep valuation premium, and mea...
Neutral
Seeking Alpha
●
etwa ein Monat alt
Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Christopher Gibson - Co-Founder, CEO & Director Najat Khan - Chief R&D Officer, Chief Commercial Officer and Director Ben Taylor - CFO & President of Recursion UK Presentation Christopher Gibson Co-Founder, CEO & Director " Najat Khan Chief R&D Officer, Chief Commercial Officer and D...
Neutral
GlobeNewsWire
●
etwa ein Monat alt
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended September 30, 2025.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
